

CRISPR Therapeutics

Land	Schweiz
Versammlungstermin	30.05.2024
Versammlungsort	Walder Wyss
GV Typ	Ordentlich
Abstimmungsfrist	29.05.2024
Art der Frist	elektronisch
Engagement-Prozess	Nein

Zusammenfassung der Generalversammlung

		Inrate	VR
1	Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the year ended December 31, 2023	Annahme	Annahme
2	Approval of the Appropriation of Financial Results	Annahme	Annahme
3	Discharge of the Members of the Board of Directors and the Executive Committee	Annahme	Annahme
4	Election or Re-election of the Members to the Board of Directors and the Chairman		
4.1	Re-election of Samarth Kulkarni, Ph.D., as member and election as Chairman	Ablehnung	Annahme
4.2	Re-election of Ali Behbahani, M.D.	Annahme	Annahme
4.3	Re-election of Maria Fardis, Ph.D.	Annahme	Annahme
4.4	Re-election of H. Edward Fleming, Jr., M.D.	Annahme	Annahme
4.5	Re-election of Simeon J. George, M.D.	Annahme	Annahme
4.6	Re-election of John T. Greene	Annahme	Annahme
4.7	Re-election of Katherine A. High, M.D.	Annahme	Annahme
4.8	Re-election of Douglas A. Treco, Ph.D.	Annahme	Annahme
4.9	Election of Sandesh Mahatme, LL.M.	Annahme	Annahme
4.10	Election of Christian Rommel, Ph.D.	Annahme	Annahme
5	Re-election of the Members of the Compensation Committee		
5.1	Re-election of Ali Behbahani, M.D.	Ablehnung	Annahme
5.2	Re-election of H. Edward Fleming, Jr., M.D.	Ablehnung	Annahme
5.3	Re-election of Simeon J. George, M.D.	Ablehnung	Annahme
5.4	Re-election of John T. Greene	Ablehnung	Annahme
6	Approval of the Compensation for the Board of Directors and the Executive Committee and Non-Binding Advisory Vote on the 2023 Compensation Report		
6.1	Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders	Annahme	Annahme
6.2	Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders	Ablehnung	Annahme
6.3	Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2024 to June 30, 2025	Annahme	Annahme
6.4	Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2024	Annahme	Annahme
6.5	Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders	Ablehnung	Annahme
6.6	Non-binding advisory vote on the 2023 Compensation Report	Ablehnung	Annahme
7	Non-Binding Advisory Vote on the Compensation Paid to the Company's Named Executive Officers under U.S. Securities Law Requirements	Ablehnung	Annahme

		Inrate	VR
8	Approval of an Increase of the Conditional Share Capital for Employee Equity Plans	Ablehnung	Annahme
9	Approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan	Ablehnung	Annahme
10	Approval of Amendments to the Articles of Association to Facilitate the Use of Equity Compensation and Pension Benefits Programs Consistent with Current Market Practices	Annahme	Annahme
11	Approval of an Increase and Certain Adjustments to the Company's Capital Band	Ablehnung	Annahme
12	Re-election of the Independent Voting Rights Representative	Ablehnung	Annahme
13	Re-election of the Auditors	Annahme	Annahme
14	Transact any Other Business that may Properly Come Before the 2024 Annual General Meeting or any Adjournment or Postponement thereof	Ablehnung	Annahme